Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
224.34B
Market cap224.34B
Price-Earnings ratio
25.77
Price-Earnings ratio25.77
Dividend yield
2.40%
Dividend yield2.40%
Average volume
2.81M
Average volume2.81M
High today
$417.45
High today$417.45
Low today
$413.44
Low today$413.44
Open price
$415.50
Open price$415.50
Volume
594.32K
Volume594.32K
52 Week high
$447.03
52 Week high$447.03
52 Week low
$288.00
52 Week low$288.00

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $414.95. The company's market cap stands at 224.34B, with a P/E ratio of 25.77 and a dividend yield of 2.40%.

During the trading session on 2026-10-12, Amgen(AMGN) shares reached a daily high of $417.45 and a low of $413.44. At a current price of $414.95, the stock is +0.4% higher than the low and still -0.6% under the high.

Trading volume for Amgen(AMGN) stock has reached 594.32K, versus its average volume of 2.81M.

The stock's 52-week range extends from a low of $288.00 to a high of $447.03.

The stock's 52-week range extends from a low of $288.00 to a high of $447.03.

AMGN News

TipRanks 5h
Amgen price target lowered to $415 from $450 at BMO Capital

BMO Capital lowered the firm’s price target on Amgen (AMGN) to $415 from $450 and keeps a Market Perform rating on the shares as part of a broader research note...

TipRanks 7h
Amgen price target raised to $328 from $317 at BofA

BofA analyst Tazeen Ahmad raised the firm’s price target on Amgen (AMGN) to $328 from $317 and keeps an Underperform rating on the shares after updating estimat...

TipRanks 7h
Amgen price target lowered to $430 from $435 at Wells Fargo

Wells Fargo lowered the firm’s price target on Amgen (AMGN) to $430 from $435 following pipeline valuation updates, while keeping an Equal Weight rating on the...

Analyst ratings

51%

of 37 ratings
Buy
32.4%
Hold
51.4%
Sell
16.2%

More AMGN News

Simply Wall St 1d
Amgen Stock Could Be 39% Undervalued Following KRAS Market Growth

has delivered a powerful run in recent years, and the question now is whether the current share price lines up with the cash flows that underpin the business. W...

Amgen Stock Could Be 39% Undervalued Following KRAS Market Growth
The Motley Fool 2d
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?

Dividend investors often focus first on yield, which can lead to an overly aggressive portfolio. For example, in the pharmaceutical sector, Pfizer (PFE +1.65%)...

How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?
Zacks 3d
Amgen Laps the Stock Market: Here's Why

Amgen (AMGN Quick QuoteAMGN - Free Report) closed at $414.87 in the latest trading session, marking a +1.82% move from the prior day. This move outpaced t...

Amgen Laps the Stock Market: Here's Why
The Motley Fool 3d
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens

Equity markets have performed well this year despite several challenges, including a shaky geopolitical landscape and rising energy prices. But how much longer...

A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens
Simply Wall St 4d
Amgen In Focus As MariTide Buzz Tests Whether The Stock Is Fully Valued

Amgen (AMGN) is back in focus after fresh attention on its obesity drug candidate MariTide, now in late-stage Phase III testing, and new precision medicine part...

Amgen In Focus As MariTide Buzz Tests Whether The Stock Is Fully Valued
TipRanks 4d
Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 Trial

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Amgen lines up a head-to-head diabetes trial that could reshape the GLP-1 landscape. The...

Zacks 4d
Stock Market News for Oct 8, 2026

Wall Street ended higher on Wednesday as market participants assessed the Federal Reserve’s rate outlook and economic data. The Nasdaq Composite, the Dow and th...

Stock Market News for Oct 8, 2026

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.